$0.524
-0.048 (-9.14%)Zum Schluss
HIT-News
HIT-Events
Health In Tech Appoints Sanjay Shrestha as CEO
Health In Tech announced the appointment of Sanjay Shrestha as CEO, effective October 20. Shrestha will succeed founder Tim Johnson, who will transition to executive chairman of the board of directors of the company on the same date. The company intends to evaluate potential acquisitions, strategic investments, partnerships and complementary business opportunities. Shrestha previously served as an independent director of Health In Tech from April 2025 to August.
Health In Tech Launches HitRix Platform, Shares Up 23%
Shares of Health In Tech are moving higher after the company announced the launch of HitRix, a new AI-powered platform "designed to simplify one of the most complex and manual workflows in the large-group self-funded health insurance market." Health In Tech expects HitRix, the company's three-year rate stabilization program and expanded carrier capacity to become more meaningful growth contributors beginning in 2027 and beyond. It said, "For brokers serving larger employers, bringing a case to market can require collecting significant volumes of employee census information, claims data, plan documents and other sensitive information; organizing files received in multiple formats; preparing submissions for different carriers and managing general underwriters; tracking responses; and manually comparing proposals. HitRix is designed to simplify that process." The company also guided its 2026 revenue to $33M, roughly in line with 2025 revenue, and below the consensus estimate of $41.19M. Shares of Health In Tech are up 23% in after-hours trading to $1.01.
Health In Tech Updates 2026 Revenue Outlook to $33 Million
Health In Tech said when announcing the launch of HitRix, its new AI-powered platform, "The Company also updated its full-year 2026 revenue outlook to approximately $33 million, roughly in line with 2025 revenue, primarily reflecting the timing of several strategic initiatives during 2026. Health In Tech expects HitRix, the Company's Three-Year Rate Stabilization Program, which is a differentiated solution designed to provide employers with greater predictability in stop-loss pricing over a multi-year period, and expanded carrier capacity, to become more meaningful growth contributors beginning in 2027 and beyond...This revised outlook primarily reflects the timing of HitRix commercialization, the Three-Year Rate Stabilization Program and additional carrier capacity, which affect the timing of new policy effective dates and related revenue recognition. The Company expects these initiatives to contribute more meaningfully in 2027 and beyond as adoption increases, carrier capacity expands and new business becomes effective."
Selling Stockholders Plan to Sell 29.53M Shares of Class A Common Stock
This filing relates to the offer and sale from time to time by the selling stockholders of up to 29.53M shares of Class A common stock. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.
Health In Tech Sees 2026 Revenue of $45M-$50M
Health In Tech still sees 2026 revenue $45M-$50M, consensus $46.81M
Ähnliche Artikel
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.








